Insmed reported $738.98M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Insmed USD 738.98M 206.6M Dec/2025
Novartis USD 44.33B 2.28B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025